| Home | Search | Study Topics | Glossary |
|
|
|
 |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||
| Sponsored by: |
Alcon Research |
| Information provided by: | Alcon Research |
| ClinicalTrials.gov Identifier: | NCT00047554 |
Purpose
To monitor iris pigmentation changes over a five year period in subjects with open-angle glaucoma or ocular hypertension who have experienced an iris pigmentation change while dosing with TRAVATAN.
| Condition | Intervention | Phase |
|
Open-Angle Glaucoma Ocular Hypertension |
Drug: TRAVATAN (travoprost ophthalmic solution) 0.004% |
Phase IV |
| Genetics Home Reference related topics: | early-onset glaucoma |
| MedlinePlus related topics: | Glaucoma High Blood Pressure |
| Drug Information available for: | Travoprost |
| Study Type: | Interventional |
| Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety Study |
| Official Title: | A Phase IV Safety Study of TRAVATAN 0.004% in Subjects With TRAVATAN Induced Iris Pigmentation Changes C-01-79. |
Eligibility
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Subjects of any race and of either sex diagnosed with open-angle glaucoma (with or without pseudoexfoliation or pigment dispersion component) or ocular hypertension who have experienced an iris pigmentation change while dosing with TRAVATAN and who are currently using TRAVATAN
Contacts and Locations| Contact: Alcon Call Center | 1-888-451-EYES (3937) |
| United States, Texas | |||||
| Alcon Call Center For Locations | Recruiting | ||||
| Multiple Cities & Multiple States, Texas, United States | |||||
| Alcon Research |
More Information
| Responsible Party: | Alcon ( Jaime Dickerson ) |
| Study ID Numbers: | C-01-79, C-01-79 |
| First Received: | October 8, 2002 |
| Last Updated: | August 4, 2008 |
| ClinicalTrials.gov Identifier: | NCT00047554 |
| Health Authority: | United States: Food and Drug Administration |
|
|
|
|
|
|
